< >

HyperAcute Immunotherapy

NewLink Genetics has multiple HyperAcute immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
NewLink Genetics Corporation Provides Operational Update and Reports Fourth Quarter and Year End 2014 Financial Results
February 26, 2015

NewLink Genetics Corporation Announces Clinical Development Milestone Achieved With Merck for Ebola Vaccine Candidate
February 19, 2015

ANNOUNCEMENTS